SPY306.66+1.11 0.36%
DIA257.07+1.80 0.71%
IXIC9,538.59-13.46 -0.14%

ACADIA Pharma Will Present Pimavanserin Data At American Society Of Clinical Psychopharmacology Meeting May 29-30

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that multiple scientific presentations and abstracts evaluating pimavanserin in clinical studies for the treatment of various central nervous system (CNS)

Benzinga · 05/21/2020 13:04

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that multiple scientific presentations and abstracts evaluating pimavanserin in clinical studies for the treatment of various central nervous system (CNS) disorders will be highlighted at the 2020 American Society of Clinical Psychopharmacology (ASCP) Virtual Annual Meeting on May 29-30, 2020.

“Our research presentations at ASCP underscore the potential clinical utility of pimavanserin in serious CNS disorders,” said Serge Stankovic, M.D., M.S.P.H., ACADIA's President. “We look forward to sharing data from our pivotal studies in negative symptoms of schizophrenia and major depressive disorder where pimavanserin has demonstrated the potential to be an important treatment option for patients, as well as new long-term safety and tolerability data of NUPLAZID® in Parkinson’s disease psychosis.”

ASCP Accepted Scientific Presentations include:

Negative Symptoms of Schizophrenia

  • Pharmaceutical Pipeline Oral Presentation: ADVANCE: Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients with Negative Symptoms of Schizophrenia on Saturday, May 30, 2020, 4:55 p.m. - 5:05 p.m. Eastern Time.
  • Poster Presentation: ADVANCE: Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients with Negative Symptoms of Schizophrenia on Saturday, May 30, 2020, 12:45 p.m. - 2:15 p.m. Eastern Time.

Depression

  • Poster Presentation: Effect of Adjunctive Pimavanserin on Suicidality in Patients with Major Depressive Disorder: Secondary Analysis from CLARITY on Friday, May 29, 2020, 12:30 p.m. - 2:00 p.m. Eastern Time.
  • Poster Presentation: Effect of Adjunctive Pimavanserin on Insomnia and Function in Patients with Major Depressive Disorder: Secondary Analysis from CLARITY on Saturday, May 30, 2020, 12:45 p.m. - 2:15 p.m. Eastern Time.
  • Poster Presentation: Pimavanserin for the Treatment of Comorbid Depression in Patients with Parkinson’s Disease on Friday, May 29, 2020, 12:30 p.m. - 2:00 p.m. Eastern Time.

Parkinson’s Disease Psychosis

  • Poster Presentation: Long-Term Evaluation of Open-Label Pimavanserin Safety and Tolerability in Parkinson’s Disease Psychosis on Saturday, May 30, 2020, 12:45 p.m. - 2:15 p.m. Eastern Time.
  • Poster Presentation: Improvement and Durability in SAPS-PD Assessment over 10 Weeks of Pimavanserin Treatment for Parkinson’s Disease Psychosis on Saturday, May 30, 2020, 12:45 p.m. - 2:15 p.m. Eastern Time.